Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Study of Sunitinib in Subjects With High Risk Renal Cell Carcinoma

This study has been withdrawn prior to enrollment.
(No participants were enrolled.)
Information provided by:
Jonsson Comprehensive Cancer Center Identifier:
First received: February 16, 2010
Last updated: July 27, 2012
Last verified: July 2012
This study is designed to explore the molecular modulatory effect of Sunitinib when given in a neoadjuvant setting prior to radical or partial nephrectomy. The study will evaluate aforementioned outcomes in 30 patients at a dose of 50mg/day for 4 weeks followed by surgery 2-4 weeks following the last dose.

Condition Intervention Phase
Renal Cell Carcinoma
Drug: Sunitinib
Other: Tumor biopsy
Procedure: Nephrectomy
Other: Biomarkers
Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Phase II, Open Label, Single Center Study of Sunitinib in Subjects With High Risk Renal Cell Carcinoma

Resource links provided by NLM:

Further study details as provided by Jonsson Comprehensive Cancer Center:

Primary Outcome Measures:
  • Time to clinical recurrence after surgery for high risk localized disease. [ Time Frame: 1 year ]

Secondary Outcome Measures:
  • Toxicity of Sunitinib when administered as neoadjuvant therapy prior to surgery [ Time Frame: 1 year ]
    Toxicities will be graded using the NCI Common Toxicity Criteria, version 3.0

  • Effect of Sunitinib on pretreatment serum levels of Vascular Endothelial Growth Factor (VEGF). Tissue levels (biopsy and pathological specimen) of total VEGF, HIF-alpha, microvessel density, and apoptotic indices (TUNNEL Staining) [ Time Frame: 1 year ]
  • Radiographically quantifiable evaluation of changes in cellular disorganization (marker of necrosis) and perfusion parameters before and during the administration of Sunitinib. [ Time Frame: 1 year ]

Enrollment: 0
Study Start Date: October 2010
Arms Assigned Interventions
Experimental: Treatment
See intervention descriptions
Drug: Sunitinib
50mg/day for 4 weeks
Other Name: Sutent
Other: Tumor biopsy
Conducted prior to administration of sunitinib therapy
Procedure: Nephrectomy
Nephrectomy 2-4 weeks after last dose of Sunitinib
Other: Biomarkers

Biomarker evaluation of blood prior to treatment, after 4 weeks of Sunitinib administration, and every three months for a year after surgery.

Biomarker evaluation of tissue prior to 4 week administration of Sunitinib


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients must be at least 18 years of age
  • Must be eligible to undergo a radical or partial nephrectomy
  • Clinical stage T1b, T2, T3, T4 and/or N1 disease as documented by abdomen/pelvis CT scan, or MRI and chest x-ray or CT chest
  • Patients must have a performance status on the ECOG scale of 0-1
  • Patients must have a pretreatment wbc > 3.0, granulocyte count > 1000/mm3, hemoglobin > 8.5 g/dL, platelet count > 100,000/mm3 and a normal PT and PTT
  • Patients must have a serum creatinine < 2.0 mg/dL
  • Patients must have adequate hepatic function with a serum bilirubin < upper limit of normal and AST/ALT < 2.5 x upper limit of normal

Exclusion Criteria:

  • Radiographic evidence of metastatic disease
  • Prior administration of immunotherapy/biotherapy/hormonal or radiation for renal cell carcinoma
  • Active secondary malignancies (other than basal cell carcinoma of the skin)
  • Serious, nonhealing wound, ulcer, or bone fracture
  • Clinically significant cardiovascular disease, New York Heart Association Grade II or greater congestive heart failure, serious cardiac arrhythmia requiring medication or Grade II or greater peripheral vascular disease within 1 year preceding Day 0
  • Any history or radiologic evidence of central nervous system disease
  • Active infection requiring parenteral antibiotics at the time of the first Sunitinib administration
  • Current or recent (within the 10 days preceding Day 0) use of oral or parenteral anticoagulants (except as required to maintain patency of preexisting, permanency indwelling IV catheters), or aspirin
  • Current, recent (within the 4 weeks preceding Day 0), or planned participation in another experimental drug study
  • Screening clinical laboratory values:

    • ANC of < 1000/uL
    • Platelet count of < 100,000/uL
    • Total bilirubin > 2.0 mg/dL
    • AST or ALT > 2.5 times the upper limit of normal
    • Serum creatinine of > 2.0 mg/dL
    • Hemoglobin of < 9 gm/dL (may be transfused to maintain or exceed this level)
    • Ongoing cardiac dysrhythmias of NCI CTCAE Version 3.0 grade > 2
    • Prolonged QTc interval on baseline EKG
    • Uncontrolled hypertension (>150/100 mm Hg despite optimal medical therapy)
    • Pre-existing thyroid abnormality with thyroid function that cannot be maintained in the normal range with medication
    • Patients receiving CYP3A4 inducers or inhibitors; patients should not take grapefruit juice or St. John's Wort while on the study
    • History of psychiatric disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that might affect the interpretation of the results of the study or render the subject at high risk from treatment complications
    • Unable to take medication by mouth
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01070186

Sponsors and Collaborators
Jonsson Comprehensive Cancer Center
Principal Investigator: Fairooz Kabbinavar, M.D. University of California, Los Angeles
  More Information

Responsible Party: Fairooz Kabbinavar, MD / Principal Investigator, UCLA Jonsson Comprehensive Cancer Center Identifier: NCT01070186     History of Changes
Other Study ID Numbers: 09-07-068
Study First Received: February 16, 2010
Last Updated: July 27, 2012

Keywords provided by Jonsson Comprehensive Cancer Center:
Kidney Cancer

Additional relevant MeSH terms:
Carcinoma, Renal Cell
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Kidney Neoplasms
Urologic Neoplasms
Urogenital Neoplasms
Neoplasms by Site
Kidney Diseases
Urologic Diseases
Antineoplastic Agents
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Physiological Effects of Drugs
Growth Inhibitors processed this record on April 28, 2017